Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 66

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic105Crohn's disease94Colorectal cancer89Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma39Pancreatic carcinoma metastatic35Adenocarcinoma pancreas34Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome29Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Endometrial cancer16Gastroenteropancreatic neuroendocrine tumour disease16+445

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Pancreatic carcinoma+1

Not recruiting

Study on Dostarlimab, Vitamin D3, and Drug Combination for Untreated Metastatic Pancreatic Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Colecalciferol
  • Sponsor:Hospital Foch

Pancreatic carcinoma metastatic

Not recruiting

Study on Durvalumab and Rintatolimod for Patients with Metastatic Pancreatic Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Anal cancer stage II+1

Not recruiting

Study on Durvalumab with Radiochemotherapy for Patients with Locally-Advanced Anal Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Goethe University Frankfurt

Gastrooesophageal cancer+1

Not recruiting

Study on Organ Preservation for Early Stage Esophageal Cancer Using Durvalumab and Chemoradiation for Patients Eligible for Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Colorectal cancer metastatic+1

Not recruiting

Study on ABBV-400 with Fluorouracil, Folinic Acid, and Bevacizumab for Adults with Unresectable Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study on Upadacitinib for Children with Moderate to Severe Crohn's Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ciprofloxacin
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Gastrointestinal stromal tumour

Not recruiting

Study of IDRX-42 for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[4-(Methyl-1H-Pyrazol-4-Yl)-Benzyl] (6[7-(3-Pyrrolidin-1-Yl-Propoxy)-Imidazo[1,2-A] Pyridin-3-Yl]-Pyrimidin-4-Yl]-Amine
  • Sponsor:Idrx Inc.

B-cell lymphoma+13

Not recruiting

Study of Fadraciclib in Adults with Advanced Solid Tumors (Including Breast, Colorectal, Endometrial, Ovarian, Biliary Tract, and Liver Cancer) and Lymphoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fadraciclib
  • Sponsor:Cyclacel Limited

Pancreatic carcinoma

Not recruiting

Study on the Effects of Calcium Chloride and Bleomycin with Electroporation Techniques for Patients with Unresectable Pancreatic Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin
  • Sponsor:Agencja Badań Medycznych

Gastrooesophageal cancer

Not recruiting

Study on Atezolizumab with Drug Combination for Patients with Gastric Cancer and Esophagogastric Junction Adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Systemic scleroderma

Not recruiting

Study of Hydroxychloroquine Safety and Effectiveness in Patients with Early Systemic Sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Hydroxychloroquine Sulfate
  • Sponsor:Azienda Ospedaliero-Universitaria Policlinico Umberto I

Colorectal cancer metastatic+2

Not recruiting

Study on the Safety and Efficacy of CR6086 and Balstilimab for Patients with Pretreated Metastatic Colorectal and Other GI Cancers

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Balstilimab
  • Sponsor:Rottapharm Biotech S.r.l.

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil205 clinical trialsOxaliplatin195 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate67 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate52 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.